Continuation Treatment Protocol for Patients Who Participated in the Adagio TVP 1012/501 Clinical Trial

Continue Providing Care for Patient Who Participated in the Adagio TVP 1012/501 Clinical Trial

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01709461

Enrollment

Registered

2012-10-18

Start date

2012-10-31

Completion date

Unknown

Last updated

2012-10-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Brief summary

the purpose of the study is to extend the use of Rasagelin Mesylate 1mg per day by subjects who participated in the Adagio TVP 1012/501 according to form 4a for additional three years.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

30 Years to 80 Years

Healthy volunteers

Inclusion criteria

* subjects who are willing to contiue this treatment. * subjects who took part in the TVP 1012/501 clinical trail.

Exclusion criteria

* subjects who didn't take part in the TVP 1012/501 clinical trail.

Countries

Israel

Contacts

Primary ContactRuth Djaldetti, Professor

ruthdjal@clalit.org.il972-9378218/9

Backup ContactYaniv roditi, Msc

yar@clalit.org.il972-39236843

Outcome results